Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections present a significant clinical challenge due to limited therapeutic options and high transmission potential. This study aimed to identify the resistance genes associated with carbapenemase production in CRKP isolates and evaluate the in vitro activity of ceftazidime/avibactam (CZA) and meropenem/vaborbactam (MEV), among other β-lactam/β-lactamase inhibitor combinations. Methods: Between October 2021 and June 2022, a total of 504 CRKP isolates were grown from patient samples in intensive care units. When duplicate patient samples were removed, the remaining 89 isolates were included in the study. Bacterial identification and antimicrobial susceptibility testing were per-formed using MALDI-TOF, Phoenix M50, and disk diffusion methods, following EUCAST guidelines. PCR analyses identified carbapenemase genes such as OXA-48, NDM, and KPC. Results: The most prevalent carbapenemase gene was OXA-48 (79.8%), followed by NDM (21.4%) and KPC (17.9%). The susceptibility rate to CZA was 82.0%, significantly higher than MEV (10.1%). All isolates were resistant to piperacillin/tazobactam and ceftolozane/tazobactam. Among MEV-resistant isolates, most carried the OXA-48 gene, while NDM was common in CZA-resistant isolates. Conclusions: CZA demonstrates high efficacy against OXA-48-producing CRKP, making it a viable treatment option in settings where OXA-48 predominates. The limited activity of MEV in this study underscores the need for molecular surveillance of resistance mechanisms to guide empirical therapy.
Lower respiratory tract (LRT) infections require rapid and accurate diagnosis. While bacterial culture remains the gold standard, multiplex PCR (mPCR) enables faster and more sensitive detection of multiple pathogens. This study evaluates the Bio-Speedy mPCR panel for 18 bacteria in comparison to conventional culture. A total of 100 LRT samples were analyzed. Complete concordance between the methods was observed in 85% of samples, with mPCR detecting pathogens slightly more frequently (62% vs. 53%). Discrepancies were primarily due to prior antibiotic therapy, low bacterial loads, colonization, or pathogens not included in the PCR panel. The sensitivity and specificity of mPCR were 79.3% and 96.8%, respectively, with negative agreement at 98.9% and positive agreement at 57.0%. Considering culture-negative but clinically relevant PCR-positive results, the sensitivity improved to 98.1% and the positive agreement to 86.7%. mPCR offers early pathogen detection, enabling timely therapy and potentially improving outcomes, particularly in intensive care settings. While culture remains indispensable for viable pathogen identification, combining mPCR with conventional methods provides complementary information, particularly when prior antibiotic use or the presence of fastidious pathogens may compromise culture results. Careful consideration of cost, patient population, and clinical context is recommended for optimal implementation of mPCR panels.
Aim: This study aimed to detect the carbapenem resistance of the Klebsiella pneumoniae strains, isolated from clinical specimens with genotypic and phenotypic methods. Material and Methods: A total of 87 Klebsiella pneumoniae strains whose carbapenem resistance was determined by disc diffusion method were included in the study. Carbapenemase was investigated using the combined disk method and polymerase chain reaction (PCR). Results: The evaluation of the PCR results demonstrated that OXA was detected in 60 (68.9%) samples, NDM was detected in 20 (22.9%), OXA + NDM in 5 (5.7%), and KPC was detected in 1 (1.1%) out of 87 clinical samples. Carbapenemase was not detected in one specimen with the PCR method. The results were found compatible with the combined disc test results for all isolates which were detected as only OXA, NDM, and KPC type carbapenemase positive. In 5 (5.7%) strains in which the co-existence of NDM and OXA type carbapenemases was detected by PCR, the combined disc method detected only OXA type carbapenemase. Conclusion: The combined disk method is inadequate in the presence of strains that have multiple carbapenemases, and also have OXA which is the most frequently detected carbapenemase in our hospital. EUCAST recommends verification by other methods in the presence of OXA-48. Genotypic methods can be used for confirmation testing. The detections of strains with NDM, multiple carbapenemases, and the first detection of KPC were striking in the study. Monitoring the spread of these strains in the hospital will be necessary for infection control.